A Randomized Trial of the Effect of Community Pharmacist Intervention on Cholesterol Risk ManagementThe Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP)
Authors:
- Ross T. TsuyukiRTRoss T. Tsuyuki
- Jeffrey A. JohnsonJJJeffrey A. Johnson
- Koon K. TeoKTKoon K. Teo
- Scot H. SimpsonSSScot H. Simpson
- Margaret L. AckmanMAMargaret L. Ackman
- Rosemarie S. BiggsRBRosemarie S. Biggs
- Andrew CaveACAndrew Cave
- Wei-Ching ChangWCWei-Ching Chang
- Vladimir DzavikVDVladimir Dzavik
- Karen B. FarrisKFKaren B. Farris
- Donna GalvinDGDonna Galvin
- William SemchukWSWilliam Semchuk
Open Access
- 27 May 2002
- journal article
- clinical trial
- Published by American Medical Association (AMA) in Archives of internal medicine (1960)
- Vol. 162 (10) , 1149-1155
Abstract
IN CANADA and the United States, approximately 40% of all deaths are attributed to cardiovascular disease, and this is expected to continue to increase with the aging of society.1,2 The modifiable risk factors for cardiovascular disease are well-known, and randomized trials have conclusively demonstrated the efficacy of lowering blood pressure, controlling blood glucose levels, and managing dyslipidemia in reducing mortality and morbidity from cardiovascular disease.3Keywords
This publication has 3 references indexed in Scilit:
- Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol LevelsNew England Journal of Medicine, 1998
- Low incidence of assessment and modification of risk factors in acute care patients at high risk for cardiovascular events, particularly among females and the elderlyThe American Journal of Cardiology, 1995
- Extending the role of the community pharmacist.BMJ, 1991